Aggribion therapeuticsA Joinzenberg-based biotech-based biotech startup that developed a RNA-based, nuclear-based technology for decreasing programmable cells has announced the completion of a seed financing round to accelerate the development of therapeutics based on the ownership of a seed to accelerate the development of € 8 million G-Des®. The
The round led by the Karma Fund and RV Investment led by MP Bitiligang with GMBH, Hessen Capital Eye, Broker Invest and Hi-Tech Grandderfunds (HTGF) investment.
Lucas LineigAkibion’s co-founder and co-chief executive officer said: “Acrebin is unlocking a whole new class of therapeutic possibilities with our approach. Our owned G-DC Nucleis allows a very specific reduction of certain subsets of certain cells on the basis of the presence of predetermined RNA hierarchy. Although we initially focus on the progress of groundbreaking accuracy oncology therapy, we believe that this method of decreasing programmable cells may have a wide application. I would like to thank our investors for their commitment to the aggrieved and to help them realize the potential of our technologyThe “
Established in 2021, Akibian is led by Dr. Michael Krohan and Lucas Lineig, co-founder and co-chief executive officer. Dr. Adele Nada has also been appointed as a board chair to support the management team. Dr. Nada is a biotech executive and founder and operator of multi-time. He is currently partner in Volun Therapeutics, a cell and gene therapy investor and an initiative partner with incubator in the United States.
Akribion Therapeutics is developing an RNA-directed, nuclear-based technology to reduce programmable cells. It has the ability to kill cells by cutting DNA and RNA in its G-DASC E-load, but only if the guide RNA and an endicatical RNA hierarchy have a highly specified match, only the target cells are affected, the healthy cells leave the damaged.
The G-DC E technology was discovered in Bren Biotech AG, and his team was discovered in Bien Biotech AG, experts from art applications during Michael and Lucas. Dr. Sholz also joined Akibian as the head of research and development.
Dr. MartinGeneral partner, Karma has added to funds: “Unique technology of Akibion enables to create a new class of oncology therapeutics. We are looking forward to working alongside these enthusiastic groups to develop new cancer treatment with advanced results of these conventional patients and to treat hintsThe “
Initially aims to HPV-Indo-Neck Cancer (OPSCC), exploring additional applications on Akibion oncology, autoimmune disease, fibrosis and infectious diseases.
The flexibility and broad potential of Akibian technology creates it as a committed platform for different therapeutic fields, as simply changing the guide RNA, the technology can be adapted to faster to target different cells, it makes it faster to develop new treatment than the traditional tidal procedure. Makes
Dr. Alexei JeffmanInvestment Director, RV Investment, Comments: “We are thrilled to support Akibian’s entrepreneurial team because they try to unlock their unique technology full potential. The high adaptability of the G-DASE-E Platform is made as a perfect tool for lifting our emerging knowledge about the genomic signature of the disease across various therapeutic regions.“
Dr. Catharina SaverinInvestment Director of HTGF, added: ”Acribion therapeutics creates great potential for the development of the therapeutic method of transforming their fancy methods to reduce the powerful team of therapeutics and RNA-guided cells. Initially when targeting cancer, there is also a great promise to adapt the multipurpose technology for future treatment for future treatment, autoimmune disease, infectious diseases, fibrosis and beyond. We are excited to be part of their journey!“
The current financing round is expected to provide Vivo proof of the concept of aggrieved technology.
[publish_date
